This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline on the screening for cervical cancer. The guideline examines the age at which to begin and end screening, the optimal interval for screening, the effectiveness of different screening strategies, and related benefits and harms of different screening strategies. Specific strategies discussed include screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years, screening every 3 years with cervical cytology alone, screening every 5 years with high-risk human papillomavirus (HPV) testing alone, and screening every 5 years with high-risk HPV testing in combination with cytology (co-testing) in women aged 30 to 65 years.

This is a clinical practice guideline for adult patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Recommendations are provided for screening, staging, diagnosis, treatment, and follow-up. Treatment options discussed include debulking surgery, chemotherapy, and radiation therapy. Management of drug reactions is also discussed.

This is a clinical practice guideline for adult oncology patients with neutropenia. The guideline examines the appropriate prescribing of filgrastim for these patients. Indications for which filgrastim should be used are discussed by disease site group. Disease site groups considered include breast, central nervous system, gastrointestinal, gynecologic, genitourinary, hematologic, and thoracic, amongst others.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for women with epithelial ovarian cancers, specifically focusing on patients with type-2 ovarian cancers. The guideline examines diagnostic imaging methods, used for both staging and evaluating potential recurrence. Imaging modalities discussed include x-ray, magnetic resonance imaging (MRI), fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and computed tomography (CT).

This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.

This is a clinical practice guideline for women with early-stage squamous cell vulvar cancer. The guideline examines sentinel lymph node biopsy (SLNB), including its safety and effectiveness in identifying women with node-negative, early-stage vulvar cancer. The appropriate procedures for SLNB in these patients are also discussed, such as selecting appropriate patients, determining the appropriate technique, and managing patients with positive sentinel lymph nodes.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for women with potentially curable, non-operable, locally advanced cervical cancer. The guideline provides recommendations on treatment using brachytherapy (BT), and compares different forms of BT such as two-dimensional BT, computed tomography-guided BT, magnetic resonance (MR)-guided intracavitary BT, and MR-guided intracavitary/interstitial BT. Outcomes of interest include survival, local tumour control, and toxicity.

This is a clinical practice guideline for women with an average risk of ovarian cancer. The guideline examines the benefits and harms of screening for ovarian cancer in these patients, including those of the screening test and of diagnostic evaluation. Screening tests considered include cancer antigen 125 (CA-125) screening and transvaginal ultrasound screening, on their own or combined. Outcomes of interest include ovarian cancer mortality, quality of life, false-positive rates, surgical complication rates, and the psychological effects of screening.

This clinical practice guideline provides recommendations on the follow-up of patients with endometrial cancer who are clinically disease free after receiving primary treatment. The guideline reviews symptomatic signs of possible recurrence. Recommendations are provided on follow-up intervals and diagnostic interventions, stratified by risk of recurrence.

This is a clinical practice guideline for women with average risk and high risk for ovarian cancer. The guideline examines the role of imaging during ovarian cancer screening, and its effectiveness in detecting ovarian cancer at an early stage, in order to potentially improve survival. Variations of procedures, including ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography using fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG-PET), are discussed, as is their appropriateness in different clinical situations.

This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.

This is a clinical practice guideline for women with recurrent epithelial ovarian cancer (EOC), including fallopian tube and primary peritoneal cancers. The guideline examines the most up-to-date systemic therapy treatment recommendations for recurrent EOC in order to promote evidence-based practice in Ontario. Outcomes of interest include improvements in progression-free survival and symptom control.

This is a clinical practice guideline for patients who may be at high-risk for developing breast and ovarian cancer due to genetic/familial predispositions. The guideline provides recommendations on genetic risk assessment and genetic counseling, and specifically discusses the management of individuals with hereditary breast or breast/ovarian syndromes, including BRCA-related breast/ovarian cancer syndrome, Li-Fraumeni syndrome, and Cowden syndrome.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

A clinical practice guideline for asymptomatic, nonpregnant adult women. The guideline discusses pelvic examination as a screening method for gynecological conditions such as bacterial vaginosis, candidiasis, genital warts, genital herpes, trichomoniasis, pelvic inflammatory disease, cervical polyps, endometriosis, ovarian cysts, dysfunction of the pelvic wall and floor, and uterine fibroids, in addition to ovarian, uterine, and vaginal cancer. This guideline does not address the screening of cervical cancer, gonorrhea, or chlamydia.

This is a clinical practice guideline for patients with epithelial ovarian-type cancers (e.g. ovary, fallopian tube or peritoneal origin) and borderline tumours. This guideline addresses epithelial cancers of varying histological subtypes. The guideline covers the full continuum of care including screening and prevention, diagnosis, treatment options such as surgery, systemic therapy and chemotherapy, follow-up, as well as management of recurrent disease. The guideline also highlights the support needs for women with ovarian cancer.

This is a clinical practice guideline for adult female patients diagnosed with advanced stage or recurrent endometrial cancer (excluding sarcomas and squamous cell carcinomas) or uterine papillary serous carcinoma. The guideline examines chemotherapeutic and hormonal therapy options for patients with these cancers. Outcomes of interest include improved response rates and survival.

This recommendations report provides guidance on the investigation and management of suspected or proven pelvic and extra-pelvic gynecologic sarcomas. Recommendations are made on the use of pathology during investigation, while recommendations pertaining to treatment focus on surgery and adjuvant therapy. The guidance document also provides recommendations on a number of quality assurance measures to assess gynecologic sarcoma services.

This is a clinical practice guideline for women with uterine cancer. The guideline provides recommendations for the screening and prevention of uterine cancer in the general population and in high risk groups, as well as for the pathological work-up, management, and follow-up of patients with uterine cancer. Specific conditions discussed include endometrioid endometrial cancer, as well as non-endometrioid cancers such as uterine serous carcinoma, uterine clear cell carcinoma, and uterine carcinosarcoma.

This is a clinical practice guideline for women presenting with suspicious adnexal masses, either symptomatic or asymptomatic. The guideline examines the optimal strategies for preoperative identification of adnexal masses that are suspicious for ovarian cancer, and the most appropriate surgical procedures for those identified.

This is a clinical practice guideline for patients with suspected or incidentally diagnosed adnexal masses. The guideline discusses the use of ultrasonography and serum marker testing during initial evaluation, which findings indicate malignant versus benign masses, and the appropriate situations for surgery versus observation. Specific recommendations are also provided for adolescents and pregnant women.

This is a clinical practice guideline for the vaccination of human papillomavirus (HPV) for the prevention of cervical cancer in women. The guideline examines the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the cross-protective ability of each HPV preventive vaccine.

This is a clinical practice guideline to guide appropriate prescribing of filgrastim in adults. The guidelines looks at a variety of disease sites and is intended as a guide to facilitate a shared approach to the appropriate use of filgrastim. In order provide clarity surrounding the indications in which filgrastim should be used, the recommendations are presented by disease site.

This clinical practice guideline provides recommendations for the diagnosis, treatment, and follow-up of epithelial ovarian cancer. This guideline covers: carcinoma of the ovary, fallopian tube and primary peritoneal carcinoma; epithelial carcinoma, e.g. serious, mucinous, clear cell or endometrioid histology; borderline and invasive disease, diagnosis and first-line treatment; and follow-up after treatment. Recommendations consider patient values and preferences when treated for ovarian cancer.

This is a clinical practice guideline for the use of myeloid growth factors in adult patients with solid tumours and non-myeloid malignancies. Benefits and risks are reviewed, the role of biosimilars is discussed, and recommendations are provided for prophylactic and therapeutic uses of both granulocyte and granulocyte-macrophage colony stimulating factors (CSFs). Recommendations are also given regarding the use of CSFs in the hematopoietic cell transplant setting. Outcomes of interest include efficacy of CSFs, mortality, length of hospitalization, toxicity, and adverse effects.

A clinical practice guideline for women with stage I ovarian cancer. The guideline examines adjuvant therapy, primarily systemic therapies, in relation to surgical staging. Outcomes of interest include overall and disease-free survival.

This is a clinical practice guideline for women with vulvar cancer (VC) or vulvar intraepithelial neoplasia (VIN). The guideline provides recommendations for symptom management, with an emphasis on self-management interventions. Specific topics discussed include the handling of surgical wounds, as well as the management of acute postsurgical pain, postsurgical urinary symptoms, and lymphedema.

This is a clinical practice guideline for females and males between the ages of 9 and 26. The guideline examines the use of the human papillomavirus (HPV) vaccination for the purposes of cancer prevention. The ages at which routine vaccination and catch-up vaccination should occur are discussed, as well as which vaccines should be used for males and females. Special populations such as men who have sex with other men and immunocompromised persons are also addressed.

This clinical practice guideline is an adoption of the American College of Physicians' 2014 guideline title Screening Pelvic Examination in Adult Women: A Clinical Practice Guideline from the American College of Physicians. The guideline examines the use of pelvic examinations to screen for noncervical cancer, pelvic inflammatory disease, or other benign gynecologic conditions in asymptomatic, non-pregnant adult women. Speculum or bimanual examinations are specifically discussed; the use of Pap tests for cervical cancer screening is not addressed in this guideline.

This is a clinical practice guideline for individuals at risk of or having genetic mutations that increase their risk of breast or ovarian cancer. The guideline reviews hereditary breast or breast/ovarian cancer syndrome, Li-Fraumeni syndrome, Cowden syndrome/PTEN Hamartoma tumor syndrome, and other genetic mutations associated with breast/ovarian cancer. Recommendations are provided for initial risk assessment, formal risk assessment and genetic counselling, and management options for individuals with a clinical diagnosis following genetic testing.

A clinical practice guideline for adult patients with recurrent endometrial cancer. The guideline examines management, including re-staging workups, and treatment through salvage radiotherapy and surgical intervention. Outcomes of interest include improved local control and 5-year survival rates through external beam radiation and brachytherapy.

This is a clinical practice guideline for palliative oncology patients 18 years of age or older with low grade/ low volume/ malignancy-associated urogenital or gastrointestinal bleeding, or with malignant gastrointestinal obstruction, compression or invasion. External beam radiotherapy (EBRT) with or without , brachytherapy, stent placement, and surgical bypass are discussed as therapeutic options. Outcomes of interest include clinical improvement of symptoms, quality of life, and survival.

This is a clinical practice guideline for women diagnosed with invasive cervical cancer. The guideline examines the most effective antitumour and palliative care interventions for clinicians and planners. Treatment options that are discussed include cone biopsy, extrafascial hysterectomy, modified radical or radical hysterectomy, and combinations of surgery, chemotherapy, and radiation therapy.

A clinical practice guideline for patients with early stage endometrial cancer. The guideline examined adjuvant therapy, including brachytherapy, radiation, chemotherapy, as well as observation in patients with low-grade/low-risk endometrial adenocarcinoma. Outcomes of interest include recurrence, local control, and overall survival.

This is a clinical practice guideline for patients with epithelial ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Less common histopathologies including ovarian low malignant potential (LMP) tumor, malignant germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumors [MMMTs] of the ovary), and malignant sex cord-stromal tumors, are also discussed. The guideline provides recommendations on diagnosis, treatment, follow-up, and relapse. Primary treatment options for ovarian cancer include surgery (risk-reducing or cytoreductive), chemotherapy (neoadjuvant and adjuvant), incomplete surgery and/or staging, anti-angiogenesis agents, and radiation therapy. The number of chemotherapy cycles and agents are reviewed, along with drug reactions.

This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

This guideline outlines the screening, diagnosis, treatment, and follow-up of human papillomavirus related cancers. The guideline examines appropriate vaccination strategies, screening (including care controversies), and treatment including chemotherapy and surgical options. Outcomes of interest include fertility sparing and reduction of unnecessary Pap testing. Provincial resources are provided.

This is a clinical practice guideline for the screening and treatment of precancerous lesions for cervical cancer prevention. The guideline focuses specifically on the screening for cervical intraepithelial neoplasia 2 & 3 and the treatment of those lesions to prevent cervical cancer in women who tested positive after screening. In formulating the recommendations, the guideline authors specifically took into account resource implications in the Saudi context.

This clinical practice guideline examines the impact of fertility drugs on the risk of cancer in women. The guideline looks at the association between use of fertility drugs and increased risk of developing invasive ovarian, breast, endometrial, colon and thyroid cancers as well as non-Hodgkin lymphoma and malignant melanoma. The association between fertility drugs and borderline ovarian tumours is also examined.

This is a clinical practice guideline for women with newly diagnosed or suspected stage IIIC or IV epithelial ovarian cancer, fallopian tub cancer, or primary peritoneal cancer. More specifically, the guideline provides guidance to clinicians and patients regarding the use of neoadjuvant chemotherapy (NACT) and interval cytoreduction. The guideline addresses a number of clinical questions including: what clinical evaluations should be performed in all women with suspected or newly diagnosed stage IIIC or IV epithelial ovarian cancer; what is the preferred chemotherapy regimen for women with stage IIIC or IV epithelial ovarian cancer who will receive NACT; and what are the treatment options for patients with progressive disease on NACT.

This is a clinical practice guideline for women who are at increased risk of developing breast cancer. The guideline provides an overview on risk assessment, risk-reduction interventions including lifestyle interventions, risk-reduction surgery, and risk-reduction agents (tamoxifen, raloxifene, aromatase inhibitors). Recommendations are also provided for managing side effects of risk-reduction agents and monitoring for complications. Risk-reduction counselling is also discussed.

A clinical practice guideline for patients with suspected uterine neoplasms. The guideline examines surveillance, diagnostic assessment, and treatment focusing primarily on surgical interventions and systemic therapy. Outcomes of interest include long-term survival and reproductive sparing.

This is a clinical practice guideline for women with vulvar carcinoma. The guideline examines the appropriate use of adjuvant therapy in these patients, following primary surgical treatment. Adjuvant radiation, including dose, fields, and technique, as well as adjuvant chemotherapy, were discussed as potential treatment options. In addition, the guideline examines the appropriateness of different imaging techniques, such as magnetic resonance imaging (MRI), fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and computed tomography (CT), for the staging of vulvar carcinoma.

This is a clinical practice guideline for the adjuvant treatment of completely resected stages I-IV uterine leiomyosarcoma. The guideline is intended to guide the safe and effective clinical use of fixed-dose rates of gemcitabine and docetaxel. Treatment outcomes are potentially curative and to improve progression-free survival, as well as overall survival.

A clinical practice guideline for female patients who have received potentially curative primary treatment for cervical cancer. The guideline examines appropriate follow-up strategies including minimum levels of screening and follow-up intervals. Outcomes of interest include recurrences detected during screening and survival rates.

An organizational guideline for the provisions of gynecologic oncology services by multidisciplinary professionals. The guideline examines the efficacy of specialist treatment, resource allocation, and the organization of work and services. Important aspects include the role of gynecologic oncologist, annual surgical case volumes, and minimum treatment standards.

A clinical practice guideline for the management of female patients with cervical cancer. The guideline examines diagnosis, staging, treatment including surgery and adjuvant therapy, and follow up. Outcomes of interest include fertility preservations and improved quality of life through hormonal replacement therapy during follow up.

This guideline outlines the screening, diagnosis, treatment, and follow-up of human papillomavirus related cancers. The guideline examines appropriate vaccination strategies, screening (including care controversies), and treatment including chemotherapy and surgical options. Outcomes of interest include fertility sparing and reduction of unnecessary Pap testing.

This is a clinical practice guideline for women with endometrial cancer, including uterine carcinosarcoma. The guideline provides recommendations on lynch syndrome screening, surgery, adjuvant treatment for completely surgically staged endometrioid carcinoma, and adjuvant treatment for surgically staged high risk histotypes including endometrial serous, clear cell, dedifferentiated/undifferentiated carcinomas and carcinosarcomas. The guideline also reviews therapy for relapsed patients, and follow-up and surveillance of women without evidence of disease after primary potentially curative treatment for any stage of endometrial cancer.

This is a clinical practice guideline for the systemic first- or second-line treatment of metastatic or locally advanced uterine leiomyosarcoma. The guide facilitates the safe and effective clinical use of fixed-dose rate gemcitabine and docetaxel. Treatment outcomes are non-curative and look to prolong progression-free survival and overall survival.

This is a systemic therapy summary for the use of dose-dense paclitaxel combined with carboplatintherapy to treat adults with stage 2-4 ovarian/fallopian/peritoneal cancer (with curative intent or to prolong survival). Treatment regimen, drug dose, and administration are reviewed, along with pre-medications, supportive care, suggested outpatient prescriptions, and recommendations for clinical monitoring and follow-up care. The guideline also addresses adverse events, precautions, dose modifications, and drug interactions.

An organizational guideline for the provision of colonoscopies to patients with abnormal cervical screening results. The guideline examines the provision of consistent quality in colonoscopies, including training and competence, practices, and quality indicators. Important aspects include training program availability, referral criteria, and group vs. individual practice requirements.

This is a clinical practice guideline for patients with epithelial ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Less common histopathologies including ovarian low malignant potential (LMP) tumour, malignant germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumours [MMMTs] of the ovary), and malignant sex cord-stromal tumours, are also discussed. The guideline provides recommendations on diagnosis, treatment, follow-up, and relapse. Primary treatment options for ovarian cancer include surgery (risk-reducing or cytoreductive), chemotherapy (neoadjuvant and adjuvant), incomplete surgery and/or staging, anti-angiogenesis agents, and radiation therapy. The number of chemotherapy cycles and agents are reviewed, along with drug reactions.

This is a clinical practice guideline for women who are at increased risk of developing breast cancer. The guideline provides an overview on risk assessment, risk-reduction interventions including lifestyle interventions, risk-reduction surgery, and risk-reduction agents (tamoxifen, raloxifene, aromatase inhibitors). Recommendations are also provided for managing side effects of risk-reduction agents and monitoring for complications. Risk-reduction counselling is also discussed.

This clinical practice guideline provides recommendations on the assessment and management of uterine leiomyomas. Treatment options reviewed include medical management, surgical therapies, uterine artery embolization, focused energy delivery systems, MR-guided focused ultrasound, and radiofrequency myolysis. Special considerations are given towards concerns about malignancy and acute uterine bleeding.

A clinical practice guideline for treatment of uterine cervical cancer. The guideline examines updated evidence on primary treatments, treatment for recurrent cancers, and additional presentations, focusing primarily of lymphadenectomy and hysterectomy. Outcomes of interest include recurrence and fertility preservation.

This guideline provides recommendations on the use of advanced practice nurses (APNs) to optimize patient, provider, and health system outcomes across the cancer care continuum. Specifically, the guideline reviews patient populations and situations (types of needs, practice settings, phase of the cancer care continuum) for which APN roles have demonstrated equivalent or improved outcomes, or reduced harms in cancer care. Outcomes of interest include quality of life, physical, functional, psychosocial, and mental health, as well as morbidity, mortality, symptom management, patient and provider satisfaction, health care utilization, costs, and quality of care.

This is a clinical practice guideline for patients with epithelial ovarian cancer. The guideline examines the clinical use of cancer biomarkers in these patients for the purposes of screening, differential diagnosis, prognosis, and monitoring. Biomarkers discussed include cancer antigen 125 (CA125) and human epididymis protein 4 (HE4). Algorithms for calculating the risk of malignancy index (RMI) including the RMI 1, RMI 2, Assessment of Different NEoplasias (adneXa), and risk of ovarian malignancy algorithm (ROMA), are also discussed.

This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

This is a clinical practice guideline for the management of endometrial cancer. Treatment recommendations are stratified by risk and include radiotherapy, chemotherapy, and surgery. Multidisciplinary care and pre-operative investigations are also discussed. Outcomes of interest include sensitivity, specificity and accuracy of pre-operative procedures, surgical adverse events (intra-operative and postoperative), quality of life, length of hospital stay, financial costs and cost effectiveness, disease-free and overall survival, loco regional recurrence rates, toxicity from adjuvant therapy, and risk of relapse.

This is a clinical practice guideline for individuals at risk of or having genetic mutations that increase their risk of breast or ovarian cancer. The guideline reviews hereditary breast or breast/ovarian cancer syndrome, Li-Fraumeni syndrome, Cowden syndrome/PTEN Hamartoma tumour syndrome, and other genetic mutations associated with breast/ovarian cancer. Recommendations are provided for initial risk assessment, formal risk assessment and genetic counselling, and management options for individuals with a clinical diagnosis following genetic testing.

A clinical practice guideline for the management of adult patients with cancer of the uterine cervix, including squamous, adenocarcinomas, and adenosquamous carcinomas. The guideline examines treatment, primarily through surgery and radiotherapy, staging, and follow-up. Outcomes of interest include improved survival benefits through chemoradiotherapy and improved outcomes thought the addition of ifosamide to recommended chemotherapies.

This guideline reviews the use of gynecological surgery for hysterectomy and myomectomy. Specific topics include morcellation techniques, diagnosis of uterine malignancy, and prognosis following surgery for uterine sarcomas. Complications with uterine morcellation are also discussed. Outcomes of interest include 5-year survival, abdominopelvic recurrence, and rate of complications.

This is a clinical practice guideline for patients of all age groups suspected of having cancers including lung and pleural, upper gastro-intestinal, lower gastrointestinal, breast, gynecological, urological, skin, head and neck, brain and central nervous system, haematological, sarcomas, and childhood cancers. Recommendations are provided on recognition and referral or investigations of cancer in primary care. Outcomes of interest include quality of life, sensitivity and specificity of diagnostic tests and signs/symptoms, positive and negative predictive values of diagnostic tests and signs/symptoms, and cost effectiveness.

This is a clinical practice guideline for cervical cancer screening for asymptomatic women aged over 20. The guideline committee considered the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papillomavirus (HPV) testing. Other areas of interest addressed in this guideline include: the age to begin and the age to terminate and screening interval; as well as the false-positive and resulting the psychological harms in screening.

This is a clinical practice guideline for patients with invasive cancer of the cervix. The guideline addresses staging techniques using imaging. This includes a review of the use of radiographs, excretory urography, transabdominal ultrasound (TRUS), computed tomography (CT), magnetic resonance imaging (MRI), lymphangiography and lymphoscintigraphy, positron emission tomography (PET) and PET/computed tomography, and nuclear medicine bone scan. Trachelectomy assessment is also discussed.

This is a systemic therapy summary for the use of bevacizumab, paclitaxel and carboplatin as therapy options for adults with recurrent, persistent or metastatic cervical cancer. Treatment regimen, drug dose, and administration are reviewed, and recommendations provided for clinical monitoring and follow-up care. The guideline also addresses adverse events, precautions, dose modifications, and drug interactions.

A clinical practice guideline for pelvic examination screening in asymptomatic, nonpregnant, adult women. The guideline examines the avoidance of unnecessary care in annual wellness visits, focusing on alternative screening methods sexually transmitted diseases and contraceptive prescription. Outcomes of interest include reduced emotional harms to patients and reduction in overdiagnosis.

This is a clinical practice guideline for female patients aged 19 and older. The guideline provides recommendations on the screening, diagnosis, treatment, and follow-up care of endometrial cancer. Prevention and risk reduction strategies are also discussed.

This clinical practice guideline provides recommendations on use of systemic therapy for women with metastatic, recurrent, or persistent cervical cancer including women with squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix. The guideline discusses use of cisplatin-paclitaxel, cisplatin-vinorelbine, cisplatin gemcitabine, and cisplatin-topotecan, and reviews the substitution of carboplatin for cisplatin in any of these combinations. Additionally, the indications for use of bevacizumab in combination with cisplatin-paclitaxel or carboplatin-paclitaxel are discussed. Primary outcomes of interest are overall survival and quality of life, with other outcomes of consideration including response rate, progression-free survival rate, and adverse effects

This is a clinical practice guideline for the diagnosis and treatment of cancer and associated malignancies in adult patients with HIV. The guideline examines the most common HIV associated cancers, Kaposi sarcoma, high grade B-cell non-Hodgkin lymphoma and invasive cervical cancer, as well as a number of other cancers with higher risk profiles in HIV patients. Outcomes of interest include improved treatment options in consideration of HAART and increased prophylactic options in low-risk patients, specifically with regards to lifestyle changes and vaccinations.

This is a clinical practice guideline for women with endometrial carcinoma. The guideline reviews treatment options including: adjuvant therapy including radiation, vaginal brachytherapy, and chemotherapy; and therapy for advanced disease. Treatment for synchronous endometrial and ovarian cancer, fertility-sparing treatment, post-treatment patient surveillance, and the role of hormone replacement therapy in the development of endometrial carcinoma are also discussed. Outcomes of interest include survival (overall, 5-year, disease-specific), locoregional recurrence rate, survival rate after recurrence, and toxicity.

A clinical practice guideline for the treatment of patients with endometrial cancer. The guideline examines the use of postoperative radiation therapy, and the use of external beam radiation or brachytherapy depending on risk factors and node status. Outcomes of interest include improved local control and improved high- and intermediate-risk treatment.

This clinical practice guideline reviews the use of chemotherapy as a treatment for epithelial ovarian cancer. Chemotherapy and biological therapies are reviewed, and scheduling is discussed. Special considerations are made to age, histological subtypes, BRCA mutations, and obesity. Outcomes of interest include survival (overall and progression-free), treatment compliance, response to chemotherapy, adverse events, and quality of life.

This guideline set provides recommendations on the management of gynecologic cancers including gynecological sarcomas and cancers of the ovary (epithelial and non-epithelial carcinomas), endometrium, uterine cervix, vulva, fallopian tube, gestational trophoblastic neoplasia, and vagina. Topics of discussion include diagnosis and staging, management, and follow-up. Additionally, prevention and screening are discussed for ovarian, endometrial, and cervical cancers. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This guideline set provides recommendations on required reports for referrals for: breast, gastrointestinal (esophagus, stomach, colon-rectum, anus, pancreas, liver, biliary tract/gall bladder), genitourinary (testis, prostate, bladder), gynecology (endometrium, cervix, ovary, vulva & vagina), head and neck (parotid & submandibular gland, thyroid, mouth, palate, nasopharynx, oropharynx, hypopharynx, nose & antrum, ear), lung, lymphoma and leukemia, melanoma, musculoskeletal and sarcoma, neuro-oncology, primary unknown, and skin (basal cell & squamous cell carcinomas, mycosis fungoides – Sezary syndrome). The guideline provides recommendations on pathology reports, operative reports, laboratory reports, and imaging reports. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This clinical practice guideline provides recommendations in relation to sentinel lymph node biopsy (SLNB) in vulvar cancer. The guideline seeks to determine whether SLNB can safely and effectively identify women with node-negative, early-stage vulvar cancer and can be used as an alternative to inguinofemoral lymph node dissection (IFLD). Additionally, the guideline provides guidance with respect to the appropriate techniques and procedures in SLNB for women with early-stage vulvar cancer. These include: the selection of appropriate patients; determining the appropriate technique, and management of patients with positive sentinel lymph nodes.

A clinical practice guideline for adult patients with advanced stage or recurrent endometrial cancer. The guideline examines the use of chemotherapy, specifically combination chemotherapy, and hormonal therapy with a specific focus on the use of cisplatin, doxorubicin, and paclitaxel. Outcomes of interest include reduced adverse effects, and improvements in progression-free survival and overall survival.

This is a clinical practice guideline for women with no signs or symptoms of BRCA-related cancer. The guideline provides recommendations on risk assessment, genetic counselling, and genetic testing for potentially harmful BRCA1 or BRCA2 mutations in asymptomatic women. The guideline also examines interventions aimed at decreasing the risk for development of BRCA-related cancer in women with potentially harmful BRCA mutations in their family. Outcomes of interest include accuracy and adverse effects of BRCA mutation testing, and effectiveness of testing and risk-reducing treatments.

This is a clinical practice guideline for patients with apparent early stage endometrial cancer at the time of diagnosis, that may have low or high risk features. The guideline examines pre-operative investigations, surgery techniques, and adjuvant treatment including radiotherapy and chemotherapy, with recommendations taking risk into consideration. The use of multidisciplinary team management is also discussed. Outcomes of interest include treatment risks, complications, and survival rates. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of July 11, 2014

This is a clinical practice guideline for patients diagnosed with or suspected of having endometrial cancer. The guideline reviews diagnostic evaluation, staging, and surgical management. The use and value of various surgical approaches including hysterectomy, lymphadenectomy, and cytoreductive surgery are discussed. Outcomes of interest include sensitivity, specificity, and positive predictive value of staging procedures, postoperative morbidity, and survival rates.

This is a clinical practice guideline for female patients aged 19 and older. The guideline provides recommendations on screening, diagnosis, treatment, and follow-up care of ovarian, fallopian tube, and primary peritoneal cancers. Prevention and risk reduction strategies are also reviewed.

This clinical practice guideline discusses cervical cancer control including: cervical cancer prevention and control programmes; community mobilization, education and counselling; HPV vaccination; screening and treatment of cervical pre-cancer; diagnosis and treatment of invasive cervical cancer; and palliative care. Treatment options for special populations including women who are pregnant and women living with HIV are also reviewed.

This is a clinical practice guideline for female patients aged 9 and above. The guideline provides recommendations on screening, diagnosis, treatment, and follow-up care of human papillomavirus (HPV) related cancers including cervical, vaginal, and vulvar. Special topics of interest include an overview of HPV vaccines and a discussion on controversies in care, including screening intervals and age to stop screening.

This is a clinical practice guideline for patients who have bowel obstruction with advanced peritoneal carcinomatosis for which complete cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion are no longer relevant. The guideline provides recommendations on clinical assessment and treatment options for relieving intestinal obstruction or its symptoms. Treatment/management options include surgery, steroids, stents, nasogastric tubes (NGT's) and venting gastronomy, antisecretory drugs, and antiemetic management. Outcomes of interest include complication rate of surgical management (e.g. obstruction, perforation), morbi-mortality rates from surgery, and quality of life.

This is a clinical practice guideline for women with endometrial cancer. The guideline provides recommendations on adjuvant therapy after surgical treatment. Radiotherapy and chemotherapy options are discussed. Postoperative progression-free and overall survival are the primary outcomes of interest.

This is a clinical practice guideline for patients diagnosed with or suspected of having gestational trophoblastic disease (GTD). The guideline reviews diagnosis, staging, management of disease, and follow-up care. Treatment options for gestational trophoblastic tumours, placental site trophoblastic tumour/epithelioid trophoblastic tumours, and drug-resistant disease are reviewed. Outcomes of interest include survival, remission rate, toxicity, prognostic factors, and disease relapse.

A clinical practice guideline for patients with, or suspected of having, HPV associated lesions of the lower anogenital tract. The guideline examines appropriate terminology for cancers of the anogenital region and provides a diagnostic and histopathologic nomenclature system for use in clinical settings. Outcomes of interest include clarified margins for squamous cells and lesions in terms of both regional definition and staging.

A clinical practice guideline for patients with endometrial cancer. The guideline examines diagnosis and treatment options for pre- and post-menopausal women, with specific focus on the surgical extent of treatment. Outcomes of interest include improved recommendations for laparoscopy and improved accuracy of lymphadenectomy for staging.

This is a clinical practice guideline for patients over 18 years of age with squamous cell carcinoma of the vulva. The guideline reviews pre-operative investigations, primary treatment, adjuvant treatment, and follow-up and surveillance, with general and stage-specific recommendations provided. Outcomes of interest include cancer-related death rate, survival (overall and disease-free), progression-free interval, local control, and recurrence rate.

This is a clinical practice guideline for adult patients over 18 years of age with epithelial ovarian cancer. The guideline provides treatment recommendations with consideration to stage, grade, and tumour type. Treatment options are discussed including various chemotherapy regimes, surgery, and radiotherapy. Treatment of recurrent disease and post-treatment follow up and surveillance are also reviewed. Outcomes of interest include overall and progression-free survival, and clinical remission.

A clinical practice guideline for adult women with no symptoms of cervical cancer who are or who have been sexually active. The guideline examines cervical cancer screening by use of the Pap test, and provides recommendations for screening intervals based on age. Outcomes of interest include mortality and/or morbidity, harms, and resource implications.

A clinical practice guideline for patients with a positive diagnosis for cervical cancer. The guideline examines diagnosis and staging, and provides treatment recommendations based on cancer stage. Specific recommendations are also provided for pregnant patients. Outcomes of interest include improved use of adjuvant post-operative radiotherapy based on pathological findings.

A clinical practice guideline for adult female patients with uterine sarcomas, including leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. The guideline examines optimal surgical staging, adjuvant therapy, and palliative therapy. Outcomes of interest include improved progression-free survival rates and improved survival with the combination of gemcitabine and docetaxel.

This is a clinical practice guideline for adult patients with cancer of the uterine cervix, including squamous, adenocarcinomas, and adenosquamous carcinomas. The guideline reviews evaluation and staging, treatment, and follow-up procedures. Management of recurrent disease is also discussed. Outcomes of interest include survival (overall, disease-free, and progression-free), overall response rate, and toxicity.

This is a clinical practice guideline for women with possible endometrial cancer. The guideline reviews the epidemiology of endometrial cancer and provides recommendations on diagnostic workup. Diagnostic procedures include biopsy, hysteroscopy, dilation and curettage, pelvic ultrasound, CT scan, and MRI. Outcomes of interest include accuracy, sensitivity, and specificity of diagnostic tests.

A clinical practice guideline for the management of women with abnormal cervical cytology and any cancer precursors. The guideline examines optimal screening for multiple patient population, including multiple cell abnormalities and pregnant women. Outcomes of interest include reduced patient risk through improved long-term testing, and improved referral pathways to other management and treatment focused guidelines.

A clinical practice guideline for adult patients with gestational trophoblastic neoplasia including invasive mole, gestational choriocarcinoma, and placental site trophoblastic tumours. The guideline examines management, including concurrent diagnoses and chemotherapy recommendations. Outcomes of interest include reduced congenital malformations in future pregnancies, and improved response rates in maintenance chemotherapy.

This clinical practice guideline reviews management/treatment of and follow-up care for women with ovarian germ cell tumours. Topics of interest include the efficacy of four cycles of etoposide and cisplatin as compared to the standard therapy with three cycles of bleomycin, etoposide, and cisplatin. Supportive care for myelosuppression is also discussed. Outcomes of interest include survival, mortality, relapse, time to progression, treatment response, and treatment complications and side effects.

This is a clinical practice guideline for patients with endometrial cancer including uterine carcinosarcoma. The guideline examines treatment options including surgery, radiotherapy, chemotherapy and hormone therapy. Therapy for relapse and follow-up and surveillance care are also reviewed. Outcomes of interest include recurrence, 5-year progression-free survival, 5-year overall survival, and toxicity.

This is a clinical practice guideline for women with histologically confirmed CIN2+ or adenocarcinoma in situ (AIS) . The guideline reviews treatment options including cryotherapy, loop electrosurgical excision procedure (LEEP)/large loop excision of the transformation zone (LLETZ), and cold knife conization (CKC). Outcomes of interest include residual/recurrent CIN2+ after treatment, and treatment complications/risks including damage to other organs, major bleeding, and minor bleeding, maternal death, HPV-negative status, premature delivery, fetal/neonatal spontaneous abortions, pelvic inflammatory disease, and inflammatory disease.

A clinical practice guideline for adult patients at risk for cervical intraepithelial neoplasia. The guideline examines screening and treatment, with specific considerations for HIV positive patients and low-resource settings. Outcomes of interest include reductions in pregnancy related risks and reduction in related infections.

This guideline provides screening recommendations for breast, cervical, and colorectal cancer, based on age and risk factors. Management of test results including mammography, cytology, occult blood test (FOBT) and colonoscopy are discussed, and potential benefits and harms are reviewed. Other testing procedures include ultrasound, stereotactic core biopsy, colposcopy, endocervical curettage, endometrial biopsy, flexible sigmoidoscopy, and colonoscopy.

This is a clinical practice guideline regarding the clinical management of Lynch syndrome (LS) (previously referred to as hereditary non-polyposis colorectal cancer; HNPCC). The guideline looks at improving the identification of LS, optimal surveillance protocols for various cancers, the role of prophylactic hysterectomy with or without oophorectomy, and appropriate surgical treatment for CRC. Other topics of discussion include the influence of lifestyle and environmental factors on the development of CRC in LS, the role of aspirin in the management of LS, prenatal diagnosis (PND) and preimplantation genetic diagnosis (PGD) in LS, and the psychosocial implications of genetic testing and surveillance.

This is a clinical practice guideline for patients with endometrial cancer. The guideline discusses limited surgery and extended surgical staging, with recommendations on the extent of surgery depending on low- or high-risk disease type. Outcomes of interest include prognostic value, survival (disease-free and overall), and negative predictive value and sensitivity of staging techniques.

A clinical practice guideline for adult patients with squamous cell carcinoma of the vulva. The guideline examines management of vulvar cancer based on staging, and follow-up protocols. Outcomes of interest include endorsement of sentinel lymph node biopsy as a standard of care and improved referral recommendations.

This is a clinical practice guideline for people of reproductive age who have problems conceiving, including individuals who are preparing for cancer treatment who may wish to preserve their fertility. Diagnosis and treatment of fertility problems are discussed.

This is a clinical practice guideline for patients diagnosed with or at risk of developing epithelial ovarian cancer. The guideline reviews risk factors and provides recommendations on screening, diagnosis, surgical management, chemotherapy, and follow-up care. Special topics of consideration include the role of prophylactic salpingo-oophorectomy in screening, and management of malignant bowel obstruction in relapsed disease. Outcomes of interest include diagnostic test accuracy, survival (overall and disease-free), response rates, quality of life, and adverse effects of treatment.

This is a clinical practice guideline on the prevention and detection of cervical cancer in non high-risk adult women. The guideline examines harms and benefits of screening, use of HPV testing and cytology as screening techniques, screening strategies for different age and risk groups, and management of abnormal screening results including colposcopy. Screening recommendations for women vaccinated against HPV16 and HPV18 are also discussed. Outcomes of interest include incidence and survival rate, sensitivity, specificity, and rate of false positives and negatives.

A clinical practice guideline describing screening recommendations for cervical cancer in asymptomatic women. The guideline examines the risks and benefits of early detection, and addresses the clinical usefulness of widespread screening.

This clinical practice guideline provides recommendations on cervical screening in asymptomatic women 21 to 65 years of age. The guideline examines age-appropriate screening intervals and test type, with comparisons made between HPV testing and cytology. This guideline updates 2003 recommendations and discusses comparisons between liquid-based cytology and HPV testing as stand alone or combined screening tools.

This is a clinical practice guideline on the management of abnormal cytology results after screening for cervical cancer. Treatment follow-up algorithms are provided, and management options include biopsy, diagnostic excisional procedure including loop electrosurgical excision procedure (LEEP) , and hysterectomy. Outcomes of interest include risk factors for developing cancer, and benefits and harms of follow-up options.

This is a clinical practice guideline for women with gestational trophoblastic neoplasia, including invasive mole, choriocarcinoma, and placental site trophoblastic tumour. The guideline provides recommendations on diagnostic assessment, staging, prognostic scoring, treatment, and follow-up procedures. Outcomes of interest include diagnostic accuracy, complete response rate, survival rate, and risk of subsequent abnormal pregnancy.

A clinical practice for patients with cervical intraepithelial neoplasia. The guideline examines the use of cryotherapy based on lesion size and other risk factors. Recommendations on technique are included, and comparisons are made to loop electrosurgical excision procedures.

This is a clinical practice guideline for non-pregnant, premenopausal women with suspected ovarian masses. The guideline examines the management of ovarian masses including blood tests, pelvic ultrasound, and MRI as diagnostic assessment tools, and additionally reviews tools for estimating risk of malignancy. Other topics include follow-up care and treatment of benign cysts. Outcomes of interest include sensitivity and specificity of diagnostic tests, effectiveness of surgery, and recurrence rates.

A clinical practice guideline detailing the use of pap smears as a screening tool for women at risk for cervical cancer. The guideline examines screening timelines, optimal sampling areas, and details the process for both professionals and patients. The guideline also examines when repeat testing and referrals for colposcopies should be conducted, and provides instructional materials and sample forms.

A clinical practice guideline for cervical screening in women who are, or have been, sexually active. The guideline provides screening timelines and recommendations for when screening is no longer necessary. Recommendations are also made for women in special circumstances, including immunocompromised patients, pregnant women, and women who have undergone full hysterectomies.

This clinical practice guideline provides recommendations for cervical cancer screening tests and intervals according to age group and risk category. Conventional cytology, liquid based cytology, and HPV testing are compared. Primary HPV testing with the use of reflex cytology following a positive HPV test result is discussed. Outcomes of interest include mortality and morbidity, accuracy and adverse effects of tests, and cost effectiveness.